Pharma giant Pfizer has stated that its experimental COVID-19 pill has the capability to cut hospitalization and death by 90% in high-risk cases. The company said that it is going to seek authorization from the US Food and Drug Administration and international regulators soon.

Several media reports have said that Pfizer's Covid pill with HIV drug cuts the risk of hospitalization or death by 89%. Reactions to the news have been overwhelming.

"Just stunning results. Pfizer's new oral therapy reduced hospitalizations by 90%. Seven deaths in the placebo group, 0 deaths in the therapy group. Implications of effective therapeutics for ending the pandemic are very, very large," commented researcher Ashish K Jha. "The pill appears to be more effective than a similar offering from Merck, which is awaiting U.S. authorization," the New York Times quoted experts as saying.

"The next chapter of anti-Covid is about to start with pills that inactivate the virus, irrespective of variants. First will be Molnupiravir in a matter of weeks, then this one," opined scientist Eric Topol.